You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
京東健康及阿裏健康回吐9%-12% 內地擬禁第三方平臺直接參與藥品網絡銷售
國家藥監局發佈《中華人民共和國藥品管理法實施條例(修訂草案徵求意見稿)》,歷時一個月公開徵求意見已正式截止。其中「徵求意見稿」中新增第三方平臺提供者不得直接參與藥品網絡銷售活動。 相關股今天回吐壓力遠超大市,尤其是阿裏健康(00241.HK)終止三連升,股價由四個月高位回落低見4.85元,現報4.89元,急吐12%,爲最傷藍籌及科指成份股,成交已達1.76億股。 京東健康(06618.HK)也終止三連升,股價由四個月高位回落低見56.1元,現報57元,回吐9%,爲表現第二差科指成份股,成交增至1,185萬股。平安好醫生(01833.HK)低見21.55元,現報21.9元,回吐3.5%。 恆指及科指分別低見21,264及4,628,現報21,280及4,640,回吐1.3%及2.5%,總成交額628億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account